Home Newsfeeds Deutsche Bank Maintains Buy on HealthEquity, Raises Price Target to $68

Deutsche Bank Maintains Buy on HealthEquity, Raises Price Target to $68

Deutsche Bank analyst George Hill maintains HealthEquity (NASDAQ:HQY) with a Buy and raises the price target from $67 to $68.

byBenzinga Newsdesk

September 8, 2022

1 minute read

Deutsche Bank analyst George Hill maintains HealthEquity (NASDAQ:HQY) with a Buy and raises the price target from $67 to $68.

P/E Ratio Insights for Gilead Sciences

By Benzinga Insights

April 27, 11:00 AM

In the current market session, Gilead Sciences Inc. (NASDAQ:GILD) stock price is at $82.75, after a 1.18% decrease.…

GILD

Agape ATP Corporation Announces $1M Share Repurchase Plan Over The Next 6 Months

By Benzinga Newsdesk

November 22, 10:05 AM

AGAPE ATP Corporation (NASDAQ:ATPC) ("ATPC" or the "Company") announced that its board of directors has authorized a share repurchase plan under which the Company may repurchase up to US$1 million of its shares over the

ATPC

News

Immutep Tuesday, It Achieved 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer

By Charles Gross

January 4, 5:56 AM

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that it has enrolled and randomised over 50% of the planned 154 patients in the TACTI-003 Phase IIb trial.

IMMP